NASDAQ · Biotechnology

Aspen Neuroscience Inc. (ASPE) Stock Price & Fundamentals

$12.10 -3.90% NASDAQ: ASPE Healthcare

Data as of Nov 16, 2026 (intraday, delayed) · Source: Financial Modeling Prep (methodology)

Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company, which engages in the development of autologous induced pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases.

Valuation

MetricValue
Price$12.10
Market Cap$351.84M
P/E Ratio—
P/B Ratio—
P/S Ratio—
EPS (TTM)—
52-Week High$14.90
52-Week Low$11.20
Dividend Yield—

Financials & Margins

MetricValue
ROE—
ROA—
ROCE—
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.11
Current Ratio4.56

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
VRTXVertex Pharmaceuticals Incorporated $535.90 -0.50% 34.56 $135.87B 0.00%
REGNRegeneron Pharmaceuticals, Inc. $955.15 -0.03% 19.22 $98.79B 0.47%
MRNAModerna, Inc. $215.00 -3.75% — $86.99B 0.00%
RVMDRevolution Medicines, Inc. $168.19 -2.38% — $36.38B 0.00%
ROIVRoivant Sciences Ltd. $39.35 -0.46% — $28.51B 0.00%
INSMInsmed Incorporated $124.24 +2.55% — $27.26B 0.00%
UTHRUnited Therapeutics Corporation $585.89 -0.89% 21.31 $24.95B 0.00%
INCYIncyte Corporation $120.77 -0.17% 55.62 $24.62B 0.00%

Ownership

Insiders Held17.17%
Institutions Held52.15%
Institutions Float Held62.97%

For Aspen Neuroscience Inc., insiders hold 17.17% of the shares, institutions hold 52.15%, according to the latest holder filings.

InsiderRoleSharesLatest Transaction
ARCH VENTURE FUND X, L.P.Beneficial Owner of more than 10% of a Class of Security3,754,9202026-11-02
ORBIMED ADVISORS, L.L.C.Beneficial Owner of more than 10% of a Class of Security3,589,1302026-11-02
THOMPSON PETER ADirector and Beneficial Owner of more than 10% of a Class of Security3,589,1302026-11-02
ARCH VENTURE PARTNERS XIV, L.P.Beneficial Owner of more than 10% of a Class of Security1,200,0002026-11-02
HASNAIN FAHEEMOfficer and Director384,6792026-11-05

Filings & documents

Aspen Neuroscience Inc. (ASPE) reports filed with the US Securities and Exchange Commission, newest first. SEC CIK 0002124080. Links open sec.gov.

Recent events (8-K)

  • Charter or bylaw amendment; Other events8-K

Source: SEC EDGAR, checked 16 Nov 2026. All filings on SEC EDGAR

Latest News

Aspen Neuroscience Announces Pricing of Initial Public Offering GlobeNewswire · Oct 30, 2026

About Aspen Neuroscience Inc.

Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company, which engages in the development of autologous induced pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases. Its product candidate, sasineprocel, is an investigational single-dose, autologous iPSC-based cell therapy for the treatment of Parkinson's disease (PD). The company was founded by Jeanne F. Loring and Andrés Bratt-Leal in 2018 and is headquartered in San Diego, CA.

Aspen Neuroscience Inc. is headquartered in US.

Aspen Neuroscience Inc. (ASPE) stock trades at $12.10 with a market capitalization of $351.84M. Over the past 52 weeks the stock has ranged between $11.20 and $14.90, and currently trades 18.8% below its 52-week high.

Official website: www.aspenneuroscience.com

Aspen Neuroscience Inc. (ASPE) — frequently asked questions

What is Aspen Neuroscience Inc. (ASPE) stock price today?

Aspen Neuroscience Inc. (ASPE) is currently trading at $12.10, down 3.9% today.

What is Aspen Neuroscience Inc.'s market cap?

Aspen Neuroscience Inc. has a market capitalization of $351.84M.

How much debt does ASPE carry?

Aspen Neuroscience Inc. has a debt-to-equity ratio of 0.11. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is ASPE's profit margin?

Aspen Neuroscience Inc. reports a net profit margin of 0.00% — the share of revenue left after every cost, including tax and interest.

What sector is ASPE in?

Aspen Neuroscience Inc. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is ASPE listed on?

Aspen Neuroscience Inc. trades on NASDAQ under the ticker ASPE.

What is ASPE's 52-week range?

Over the last year Aspen Neuroscience Inc. has traded between $11.20 and $14.90.

Related Healthcare Stocks

VRTX Vertex Pharmaceuticals Incorporated $535.90 -0.50% REGN Regeneron Pharmaceuticals, Inc. $955.15 -0.03% MRNA Moderna, Inc. $215.00 -3.75% RVMD Revolution Medicines, Inc. $168.19 -2.38% ROIV Roivant Sciences Ltd. $39.35 -0.46% INSM Insmed Incorporated $124.24 +2.55% UTHR United Therapeutics Corporation $585.89 -0.89% INCY Incyte Corporation $120.77 -0.17% ALNY Alnylam Pharmaceuticals, Inc. $161.68 -2.03% ASND Ascendis Pharma A/S - Ordinary Share $272.12 -1.19% EXEL Exelixis, Inc. $67.81 -1.73% NBIX Neurocrine Biosciences, Inc. $167.08 -0.19%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens ASPE currently matches

On the figures above, Aspen Neuroscience Inc. passes the filters for 5 of our ready-made screens, among them Small Cap Stocks, Stocks Under $100, Stocks Under $50. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

Small Cap StocksStocks Under $100Stocks Under $50Debt to Equity Below 1 StocksHigh Current Ratio Stocks

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.